Vertex Pharmaceuticals Incorporated $VRTX Stock Holdings Increased by May Hill Capital LLC

May Hill Capital LLC lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.3% during the second quarter, Holdings Channel reports. The institutional investor owned 673 shares of the pharmaceutical company’s stock after buying an additional 40 shares during the quarter. May Hill Capital LLC’s holdings in Vertex Pharmaceuticals were worth $300,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Activest Wealth Management purchased a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at approximately $25,000. Clal Insurance Enterprises Holdings Ltd boosted its position in Vertex Pharmaceuticals by 450.0% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 45 shares during the last quarter. Flaharty Asset Management LLC acquired a new stake in Vertex Pharmaceuticals during the first quarter valued at $32,000. American National Bank & Trust boosted its position in Vertex Pharmaceuticals by 515.4% during the second quarter. American National Bank & Trust now owns 80 shares of the pharmaceutical company’s stock valued at $36,000 after purchasing an additional 67 shares during the last quarter. Finally, Solstein Capital LLC acquired a new stake in Vertex Pharmaceuticals during the second quarter valued at $40,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on VRTX shares. Scotiabank cut their target price on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 5th. BMO Capital Markets set a $530.00 price target on Vertex Pharmaceuticals and gave the company an “outperform” rating in a research note on Tuesday, August 5th. Leerink Partners raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their price objective for the company from $458.00 to $456.00 in a report on Thursday, September 25th. UBS Group set a $553.00 price objective on Vertex Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 5th. Finally, Royal Bank Of Canada reduced their target price on Vertex Pharmaceuticals from $430.00 to $405.00 and set a “sector perform” rating on the stock in a report on Tuesday, August 5th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $494.38.

Vertex Pharmaceuticals Trading Down 0.3%

Shares of Vertex Pharmaceuticals stock opened at $420.17 on Tuesday. The company has a market capitalization of $107.73 billion, a PE ratio of 30.03 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The stock’s fifty day simple moving average is $399.56 and its 200 day simple moving average is $433.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. The firm had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company’s revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insider Transactions at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs bought 5,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was purchased at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.